Risk for renal injury in diabetic hypertensive patients

References

• Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982: 285(6343): 685–8
   PubMed Web of Science ®Google Scholar
• Parving HH, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983: 1(8335): 1175–9
   PubMed Web of Science ®Google Scholar
• Parving HH, Andersen AR, Hommel E, et al. Effects of long-term antihypertensive treatment on kidney function in diabetic nephropathy. Hypertension 1985: 7(6 Pt 2): 11114–7
   Google Scholar
• Bakris GL, Frohlich ED. The evolution of antihypertensive therapy: an overview of four decades of experience. J Am Coll Cardiol 1989: 14(7): 1595–608
   PubMed Web of Science ®Google Scholar
• Moser M. Diuretics in the management of hypertension. Med Clin North Am 1987: 71(5): 935–46
   PubMed Web of Science ®Google Scholar
• Struthers AD, Murphy MB, Dollery CT. Glucose tolerance during antihypertensive therapy in patients with diabetes mellitus. Hypertension 1985: 7(6 Pt 2): 1195–101
   Google Scholar
• Trost BN, Weidmann P, Beretta-Piccoli C. Antihypertensive therapy in diabetic patients. Hypertension 1985: 7(6 Pt 2): 11102–8
   Google Scholar
• Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and Captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989: 321(13): 868–73
   PubMed Web of Science ®Google Scholar
• Walker WG, Hermann J, Yin DP, et al. Diuretics accelerate diabetic nephropathy in hypertensive insulin-dependent and non-insulin-dependent subjects. Trans Assoc Am Physicians 1987: 100: 305–15
   PubMedGoogle Scholar
• Warram JH, Laffel LM, Valsania P, et al. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991: 151 (7): 1350–6
   PubMedGoogle Scholar
• Parving HH, Andersen AR, Smidt UM, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987: 294(6585): 1443–7
   PubMed Web of Science ®Google Scholar
• Fuller JH, Shipley MJ, Rose G, et al. Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall study. Lancet 1980: 1(8183): 1373–6
   PubMed Web of Science ®Google Scholar
• Houston MC. Treatment of hypertension in diabetes mellitus. Am Heart J 1989: 118(4): 819–29
   PubMed Web of Science ®Google Scholar
• Bakris GL, Wilson DM, Burnett JC Jr. The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol. Circulation 1986: 74(5): 1061–5
   PubMed Web of Science ®Google Scholar
• Bakris GL. The effects of calcium antagonists on renal hemodynamics, urinary protein extraction and glomerular morphology in diabetic states. J Am Soc Nephrol (in press)
   Google Scholar
• Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: results of a double-blind, randomized, multicenter trial. N Engl J Med 1986: 315(7): 423–9
   PubMed Web of Science ®Google Scholar
• The Danish Verapamil Infarction Trial II-DAVIT II: effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 1990: 66(10): 779–85
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987: 316(23): 1429–35
   PubMed Web of Science ®Google Scholar
• Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986: 314(24): 1547–52
   PubMed Web of Science ®Google Scholar
• Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 1985: 72(4): 853–64
   PubMed Web of Science ®Google Scholar
• Weidmann P, Gerber A, Mordasini R. Effects of antihypertensive therapy on serum lipoproteins. Hypertension 1983: 5(5 Pt 2): 111120–31
   Google Scholar
• Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs. Drugs 1986: 32(4): 335–57
   PubMed Web of Science ®Google Scholar
• Charles S, Ketelslegers JM, Buysschaert M, et al. Hyperglycemic effect of nifedipine. BMJ 1981: 283(6283): 19–20
   PubMedGoogle Scholar
• Palumbo G, Barantani E, Pozzi F, et al. Long-term nifedipine treatment and glucose homeostasis in hypertensive patients. Curr Ther Res 1988: 43(1): 171–9
   Web of Science ®Google Scholar
• Giugliano D, Torella R, Cacciapuoti F, et al. Impairment of insulin secretion in man by nifedipine. Eur J Clin Pharmacol 1980: 18(5): 395–8
   PubMed Web of Science ®Google Scholar
• Pedersen EB. Some aspects of kidney function, the renin-aldosterone system and sympathetic activity in essential hypertension. Acta Med Scand Suppl 1980: 636: 1–66
   PubMedGoogle Scholar
• Bauer JH. Role of angiotensin converting enzyme inhibitors in essential and renal hypertension: effects of Captopril and enalapril on reninangiotensin-aldosterone, renal function and hemodynamics, salt and water excretion, and body fluid composition. Am J Med 1984: 77(2A): 43–51
   PubMed Web of Science ®Google Scholar
• Remuzzi A, Puntorieri S, Battaglia C, et al. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990: 85(2): 541–9
   PubMed Web of Science ®Google Scholar
• Dunn MJ. Prostaglandins, angiotension II, and proteinuria. Nephron 1990: 55(Suppl 1): 30–7
   PubMedGoogle Scholar
• Zatz R, Anderson S, Meyer TW, et al. Lowering of arterial pressure limits glomerular sclerosis in rats with renal ablation and in experimental diabetes. Kidney Int Suppl 1987: 20: S123–9
   PubMedGoogle Scholar
• Keane WF, Anderson S, Aurell M, et al. Angiotensin converting enzyme inhibitors and progressive renal insufficiency: current experience and future directions. Ann Intern Med 1989: 111(6): 503–16
   PubMed Web of Science ®Google Scholar
• Dzau VJ. Evolving concepts of the reninangiotensin system: focus on renal and vascular mechanisms. Am J Hypertens 1988: 1(4 Pt 2): 334–7S
   Google Scholar
• Loutzenhiser R, Epstein M. Effects of calcium antagonists on renal hemodynamics. Am J Physiol 1985: 249(5 Pt 2): F619–29
   PubMed Web of Science ®Google Scholar
• Magometschnigg D, Hortnagl H, Rameis H. Diltiazem and verapamil: functional antagonism of exogenous noradrenaline and angiotensin II in man. Eur J Clin Pharmacol 1984: 26(3): 303–7
   PubMed Web of Science ®Google Scholar
• Millar JA, McLean K, Reid JL. Calcium antagonists decrease adrenal and vascular responsiveness to angiotensin II in normal man. Clin Sci 1981: 61(Suppl 7): 65–8s
   Google Scholar
• Nagao T, Yamaguchi I, Narita H, et al. Calcium entry blockers: antihypertensive and natriuretic effects in experimental animals. Am J Cardiol 1985: 56(16): 56–61H
   Google Scholar
• Anderson S. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension 1991: 17(3): 288–95
   PubMed Web of Science ®Google Scholar
• Simon G, Morioka S, Snyder DK, et al. Increased renal plasma flow in long-term enalapril treatment of hypertension. Clin Pharmacol Ther 1983: 34(4): 459–65
   PubMed Web of Science ®Google Scholar
• Marre M, Leblanc H, Suarez L, et al. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. BMJ 1987: 294(6585): 1448–52
   PubMed Web of Science ®Google Scholar
• Cody RJ. The hemodynamics of calcium-channel antagonists in hypertension: vascular and myocardial responses. Circulation 1987: 75(1 Pt 2): 1175–9
   Google Scholar
• Bauer JH, Sunderrajan S, Reams G. Effects of calcium entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics, salt and water excretion and body fluid composition. Am J Cardiol 1985: 56(16): 62–7H
   PubMedGoogle Scholar
• Sunderrajan S, Reams G, Bauer JH. Renal effects of diltiazem in primary hypertension. Hypertension 1986: 8(3): 238–42
   PubMed Web of Science ®Google Scholar
• Zeller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991: 324(2): 78–84
   PubMed Web of Science ®Google Scholar
• Folkow B. Structural myogenic, humoral and nervous factors controlling peripheral resistance. In: Harrington M, ed. Hypotensive drugs. Elmsford, NY: Pergamon Press, 1956: 163–74
   Google Scholar
• Lever AF. Slow pressor mechanisms in hypertension: a role for hypertrophy of resistance vessels? J Hypertens 1986: 4(5): 515–24
   PubMed Web of Science ®Google Scholar
• Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986: 77(6): 1993–2000
   PubMed Web of Science ®Google Scholar
• Austin MB, Robson RA, Bailey RR. Effect of nifedipine on renal function of normal subjects and hypertensive patients with renal function impairment. NZ Med J 1983: 96(743): 829–31
   Web of Science ®Google Scholar
• Guazzi MD, De Cesare N, Galli C, et al. Calcium-channel blockade with nifedipine and angiotensin converting—enzyme inhibition with Captopril in the therapy of patients with severe primary hypertension. Circulation 1984: 70(2): 279–84
   PubMed Web of Science ®Google Scholar
• Dworkin LD, Parker M, Ferner HD. Nifedipine decreases glomerular injury in rats with remnant kidneys by inhibiting glomerular hypertrophy. (Abstr) Kidney Int 1989: 35(1): 427A
   Web of Science ®Google Scholar
• Yoshioka T, Shiraga H, Yoshida Y, et al. “Intact nephrons” as the primary origin of proteinuria in chronic renal disease: study in the rat model of subtotal nephrectomy. J Clin Invest 1988: 82(5): 1614–23
   PubMed Web of Science ®Google Scholar
• Harris DC, Hammond WS, Burke TJ, et al. Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987: 31(1): 41–6
   PubMed Web of Science ®Google Scholar
• Eliahou HE, Cohen D, Herzog D, et al. The control of hypertension and its effect on renal function in rat remnant kidney. Nephrol Dial Transplant 1988: 3(1): 38–44
   PubMedGoogle Scholar
• Dworkin LD, Parker M, Tolbert E, et al. Nifedipine and enalapril decrease glomerular injury in rats with remnant kidneys by different mechanisms. (Abstr) J Am Soc Nephrol 1990: 1(4): 627
   Google Scholar
• Rosenthal T, Tosenmann E, Cohen AM. Effects of nisoldipine on hypertension and glomerulosclerosis in Cohen diabetic rat with Goldblatt hypertension. (Abstr) Am J Hypertens 1990: 3(5 Pt 2): 27A
   PubMedGoogle Scholar
• Jackson B, Debrevi L, Whitty M, et al. Progression of renal disease: effects of different classes of antihypertensive therapy. J Hypertens 1986: 4(Suppl 5): S269–71
   PubMed Web of Science ®Google Scholar
• Jackson B, Cubela R, Debrevi L, et al. Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. J Cardiovasc Pharmacol 1987: 10(Suppl 10): S167–9
   PubMedGoogle Scholar
• Harris DC, Chan L, Schrier RW. Remnant kidney hypermetabolism and progression of chronic renal failure. Am J Physiol 1988: 254(2 Pt 2): F267–76
   PubMed Web of Science ®Google Scholar
• Goligorsky MS, Chaimovitz C, Rapoport J, et al. Calcium metabolism in uremic nephrocalcinosis: preventive effect of verapamil. Kidney Int 1985: 27(5): 774–9
   PubMed Web of Science ®Google Scholar
• Nelson RG, Pettitt DJ, Carraher MJ, et al. Effect of proteinuria on mortality in NIDDM. Diabetes 1988: 37(11): 1499–504
   PubMed Web of Science ®Google Scholar
• Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984: 310(6): 356–60
   PubMed Web of Science ®Google Scholar
• Bjorck S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 1986: 293(6545): 471–4
   PubMed Web of Science ®Google Scholar
• Hommel E, Parving HH, Mathiesen E, et al. Effect of Captopril on kidney function in insulin-dependent diabetic patients with nephropathy. BMJ 1986: 293(6545): 467–70
   PubMed Web of Science ®Google Scholar
• Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by Captopril in insulin dependent diabetics with nephropathy. BMJ 1988: 297(6656): 1086–91
   PubMedGoogle Scholar
• Marre M, Chatellier G, Leblanc H, et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988: 297(6656): 1092–5
   PubMedGoogle Scholar
• Ruilope LM, Miranda B, Morales JM, et al. Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis 1989: 13(2): 120–6
   PubMed Web of Science ®Google Scholar
• Eliahou HE, Cohen D, Hellberg B, et al. Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol 1988: 8(4): 285–90
   PubMed Web of Science ®Google Scholar
• Herlitz H, Nyberg G, Granerus G, et al. Effects of felodipine in patients with refractory hypertension and progressive renal disease. Scand J Urol Nephrol Suppl 1988: 108: 31–4
   PubMedGoogle Scholar
• Ambroso GC, Como G, Scalamogna A, et al. Treatment of arterial hypertension with nifedipine in patients with chronic renal insufficiency. Clin Nephrol 1985: 23(1): 41–5
   PubMed Web of Science ®Google Scholar
• Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990: 112(9): 707–8
   PubMed Web of Science ®Google Scholar
• Barnhill N, Bakris GL. The combined effects of verapamil and lisinopril on urinary protein excretion in diabetic nephropathy. J Am Soc Nephrol (Abstr) 1990: 1(4): 304A
   Google Scholar
• Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990: 113(12): 987–8
   PubMed Web of Science ®Google Scholar
• Mickisch O, Schmid M, Mann JF, et al. [Calcium antagonists in chronic renal failure: undesirable effects on glomerular hemodynamics?] Dtsch Med Wochenschr 1988: 113(40): 1546–8 (Ger, Eng abstract)
   PubMed Web of Science ®Google Scholar
• Mimran A, Insua A, Ribstein J, et al. Contrasting effects of Captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertens 1988: 6(11): 919–23
   PubMed Web of Science ®Google Scholar
• Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991: 302(6770): 210–6
   PubMedGoogle Scholar
• Baba T, Murabayashi S, Takebe K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial. Diabetologia 1989: 32(1): 40–4
   PubMed Web of Science ®Google Scholar
• Heeg JE, de Jong PE, van der Hem GK, et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989: 36(2): 272–9
   PubMed Web of Science ®Google Scholar
• MacGregor GA, Pevahouse JB, Cappuccio FP, et al. Nifedipine, diuretics and sodium balance. J Hypertens Suppl 1987: 5(4): S127–31
   PubMedGoogle Scholar
• Julian BA, Cannon VR, Waldo FB, et al. Macroscopic hematuria and proteinuria preceding renal IgA deposition in patients with IgA nephropathy. Am J Kidney Dis 1991: 17(4): 472–9
   PubMed Web of Science ®Google Scholar
• Lipson LG. Special problems in treatment of hypertension in the patient with diabetes mellitus. Arch Intern Med 1984: 144(9): 1829–31
   PubMedGoogle Scholar
• Tuttle KR, Bruton JL, Perusek MC, et al. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991: 324(23): 1626–32
   PubMed Web of Science ®Google Scholar